Recent advances in Parkinson disease

S. Chandra, M. Srivastav, N. Chauhan
{"title":"Recent advances in Parkinson disease","authors":"S. Chandra, M. Srivastav, N. Chauhan","doi":"10.26510/2394-0859.PBE.2017.22","DOIUrl":null,"url":null,"abstract":"The article reviewed various therapies other than dopamine treatment like A2a antagonists: antiparkinson medication reducing the over reactivity of substantia nigra due to loss of dopamine; Levodopa/Carbidopa Intestinal Gel: an aqueous gel containing levodopa and carbidopa; stem-cell therapies like embryonic and adult stem cell can be act through several mechanism; acupuncture: reduced the motor symptoms and other disease related factors; various antiparkinson medications like IPX066 and ND0611 are sustained release and transdermal patches which are transported to GIT through high nutrients and patches are found to be useful in increasing the concentration, half-life of levodopa, thus downs the threatening risk of PD. The future treatment for PD should be considered as they have less side-effect and better results than other treatment as they not only decrease the symptoms but also the incidences of PD. If the symptoms are diagnosed early patient should go for genetic therapy to relieve from the disease which not only reduce the progressive increase of symptoms and disease. Considering all therapies, future treatments shows the weightage in reducing the progressive increase of PD in patient. Though these treatments are proven to be effective in treatment but still more targeted tools and techniques are required which can specifically target the cause and thus lowers the graph and rating scale of PD.","PeriodicalId":19998,"journal":{"name":"Pharmaceutical and Biological Evaluations","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical and Biological Evaluations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26510/2394-0859.PBE.2017.22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The article reviewed various therapies other than dopamine treatment like A2a antagonists: antiparkinson medication reducing the over reactivity of substantia nigra due to loss of dopamine; Levodopa/Carbidopa Intestinal Gel: an aqueous gel containing levodopa and carbidopa; stem-cell therapies like embryonic and adult stem cell can be act through several mechanism; acupuncture: reduced the motor symptoms and other disease related factors; various antiparkinson medications like IPX066 and ND0611 are sustained release and transdermal patches which are transported to GIT through high nutrients and patches are found to be useful in increasing the concentration, half-life of levodopa, thus downs the threatening risk of PD. The future treatment for PD should be considered as they have less side-effect and better results than other treatment as they not only decrease the symptoms but also the incidences of PD. If the symptoms are diagnosed early patient should go for genetic therapy to relieve from the disease which not only reduce the progressive increase of symptoms and disease. Considering all therapies, future treatments shows the weightage in reducing the progressive increase of PD in patient. Though these treatments are proven to be effective in treatment but still more targeted tools and techniques are required which can specifically target the cause and thus lowers the graph and rating scale of PD.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
帕金森病的最新进展
本文综述了除A2a拮抗剂等多巴胺治疗外的各种治疗方法:抗帕金森药物可减少因多巴胺缺失引起的黑质过度反应性;左旋多巴/卡比多巴肠凝胶:一种含有左旋多巴和卡比多巴的水凝胶;干细胞治疗,如胚胎干细胞和成体干细胞,可以通过几种机制起作用;针灸:减轻运动症状等疾病相关因素;各种抗帕金森药物如IPX066和ND0611是缓释和透皮贴剂,通过高营养转运到GIT,贴剂被发现有助于增加左旋多巴的浓度和半衰期,从而降低PD的威胁风险。与其他治疗方法相比,它们的副作用更小,效果更好,不仅可以减轻PD的症状,还可以降低PD的发病率,因此应该考虑未来的治疗方法。如果症状得到早期诊断,患者应进行基因治疗以缓解疾病,这不仅可以减少症状和疾病的进行性增加。考虑到所有的治疗方法,未来的治疗方法在减少患者PD的进行性增加方面发挥了重要作用。虽然这些治疗方法被证明是有效的,但仍然需要更有针对性的工具和技术来专门针对病因,从而降低PD的图表和评分量表。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Preliminary toxicity and gastroprotective potential of flavonoid-rich fractions of leaves from Opilia celtidifolia (Guill. & Perr.) Endl. ex Walp (Opiliaceae) Molecular structure, HOMO, LUMO, MEP, natural bond orbital analysis of benzo and anthraquinodimethane derivatives Synthesis and evaluation trypanosomicidal activity of new derivatives of megazol Polycystic ovarian syndrome: a curse to young women’s Evaluation of analgesic activity of ethanolic and aqueous extracts of leaf of Plumeria rubra in albino rat
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1